Click on a person to read their bio.
Alternative Investment Platforms
Dr. Gallagher joined Frazier Healthcare’s life science team in October of 2013 as a Venture Partner. Prior to Frazier, Dr. Gallagher was President and CEO of Calistoga Pharmaceuticals, a Frazier-founded company based on a set of novel, preclinical assets spun out of Icos Pharmaceuticals. Dr. Gallagher together with an experienced team she helped to build, advanced a first-in-class product (CAL-101, now called idelalisib) through definitive, proof-of-concept studies in patients with certain lymphomas and leukemias. These efforts ultimately led to the acquisition of Calistoga by Gilead Sciences in 2011 for a total consideration of $600 million. Dr. Gallagher currently serves on several biotech boards, including AnaptysBio and Atterocor, both of which are Frazier portfolio companies. Dr. Gallagher attended Vanderbilt University and received Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky. She started her career at Eli Lilly and Company and held roles of increasing responsibility with Amgen, Agouron/Pfizer, Biogen Idec, CancerVax and Anadys Pharmaceuticals.
Audrey brings 20 years’ experience in global strategic marketing firms to build businesses and their brands. OurCrowd is the world’s leading equity crowdfunding platform that gives accredited investors an innovative, new way to find and invest in startups. Since its inception in February 2013, OurCrowd investors have invested over $34M into 33 portfolio companies. Their investor community spans 20 countries and collectively commands an expansive set of connections and skills, helping their portfolio companies to grow. OurCrowd has allowed individuals to invest alongside top-tier venture capital firms like Horizon Ventures, Jerusalem Venture Partners, Cedar Fund, Khosla Ventures, Carmel, Index, Accel, Israel Cleantech Ventures, Aleph Fund, Pontifax, and others. Jon Medved, one of Israel’s most well-known venture capitalists, created OurCrowd to solve a traditional dilemma for angel investors. Angels have the flexibility and freedom to choose their own deals and are not forced to make a large upfront commitment as they would in a venture fund. However, venture funds have access to the best deal flow and work with professional diligence teams, and they regularly invest on better legal terms than angels are able to. OurCrowd solves this dilemma by providing angels an online platform where a professional diligence team has sourced and negotiated deals, publishing them online only after OurCrowd has already invested its own money. Once published online, these deals are open for investors to browse through and select from.
As a founder and Managing Director of Correlation Ventures, David helps lead the firm, including managing its Life Science and Clean Tech investment practices. David created the original vision for Correlation, driven by the opportunity to offer entrepreneurs and other VCs a better co-investment option and to pioneer the use of predictive analytics in venture capital. David began his venture capital career in 1997. Prior to Correlation, David was a Managing Director of Hamilton BioVentures, an early-stage venture capital fund. As head of Hamilton’s Life Science team, David served on the Board of Directors of such companies as PhotoThera, Transcept (NASDAQ: TSPT), and Egea Biopharmaceuticals (Acquired by Johnson&Johnson). Previously, David was a Venture Partner at Windamere Venture Partners and President of Forge Medical Ventures, an early-stage incubator funded by Enterprise Partners, Mayfield Fund and Johnson & Johnson Development Corporation. David was the Founder of Spine Wave, a venture-funded medical device company and Director of Business Development of UroMed Corporation (URMD), a venture-funded startup that raised several rounds of venture capital and completed a public offering. David received an M.B.A. from the Harvard Graduate School of Business Administration and graduated Summa Cum Laude with a B.S. in Biology from Princeton University.
Dr. Ralph J. Greenspan, Director of the Center for Brain Activity Mapping of the Kavli Institute for Brain and Mind at the UC San Diego
Dr. Ralph J. Greenspan has worked on the genetic basis of behavior and brain function in fruit flies (Drosophila melanogaster) almost since the inception of the field, studying with one of its founders, Jeffery Hall, at Brandeis University in Massachusetts, where he received his Ph.D. in biology in 1979. He is currently Director of the Center for Brain Activity Mapping of the Kavli Institute for Brain and Mind at the University of California San Diego, and Professor in the Division of Biology’s Neurobiology Section and the Dept. of Cognitive Science. Dr. Greenspan’s research includes studies of the consequences of mutations and localized genetic alterations in the nervous, molecular identification of genes causing naturally occurring variation in behavior, and the genetic analysis of fruit fly sleep and attention. His current research addresses large-scale network interactions pertaining to the action of genes and neurons. In 2011, he was one of the small team of scientists that produced the white paper for the White House Office of Science and Technology Policy that eventuated in the BRAIN Initiative. In addition to research papers, he has authored: Fly Pushing: The Theory and Practice of Drosophila Genetics, , An Introduction to Nervous Systems, and How Genes Influence Behaviour (with Jonathan Flint and Ken Kendler).
Dr. Wahl is passionate about treating elite and recreational athletes and is nationally known for his expertise in the treatment of complex knee and shoulder injuries. In 2013, Dr. Wahl was named the head team physician for the San Diego Chargers. Prior to joining UC San Diego Health System, Dr. Wahl served as team physician for many University of Washington sports teams, including football, men’s basketball, volleyball, softball, gymnastics and tennis. As part of an American Orthopedic Society for Sports Medicine traveling fellowship, he visited many sports facilities and hospitals throughout South America. Dr. Wahl completed his residency training and earned his medical degree from Yale University. He completed a sports medicine and shoulder surgery fellowship at the prestigious Hospital for Special Surgery in New York City. He then went on to complete a trauma fellowship in Germany and Switzerland as an A.O. John Border Traveling Trauma Fellow. In addition to his work with athletics, Dr. Wahl has a national reputation as a skilled surgeon, inspirational teacher and compassionate doctor, and has been named a “Top Doctor” by San Diego Magazine in orthopedics and sports medicine surgery. Dr. Wahl enjoys cycling, sailing, running, surfing and skiing with his wife and their three young children.
Since 1994, Professor Lee has been a Professor of Electrical Engineering at Stanford University where his research focus has been on gigahertz-speed wireline and wireless integrated circuits built in conventional silicon technologies, particularly CMOS. He is an award winning writer, authoring numerous books including The Design of CMOS Radio-Frequency Integrated Circuits (now in its second edition), and Planar Microwave Engineering, both with Cambridge University Press. He served for a decade as an IEEE Distinguished Lecturer of the Solid-State Circuits Society, and has been a DL of the IEEE Microwave Society as well. Tom cofounded Matrix Semiconductor (acquired by Sandisk in 2006) and is the founder of ZeroG Wireless. In early April of 2011 he was awarded the Ho-Am Prize in Engineering (colloquially known as the “Korean Nobel”).